BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3828988)

  • 1. Correlation between antitumor activity of protein A and in vivo formation of defined high molecular weight complexes with immunoglobulin G in BALB/c mice.
    Das C; Langone JJ
    Cancer Res; 1987 Apr; 47(8):2002-7. PubMed ID: 3828988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissociation between murine spleen cell mitogenic activity of enterotoxin contaminants and anti-tumor activity of staphylococcal protein A.
    Das C; Langone JJ
    J Immunol; 1989 Apr; 142(8):2943-8. PubMed ID: 2703712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of complexes containing protein A and rabbit immunoglobulin G or Fc gamma fragments.
    Das C; Shearer WT; Langone JJ
    Res Commun Chem Pathol Pharmacol; 1986 Jan; 51(1):117-28. PubMed ID: 3952366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment by blocking its binding to the alpha subunit of the interleukin 2 receptor in the circulation with preinjected humanized anti-Tac IgG.
    Kobayashi H; Yoo TM; Drumm D; Kim MK; Sun BF; Le N; Webber KO; Pastan I; Waldmann TA; Paik CH; Carrasquillo JA
    Cancer Res; 1997 May; 57(10):1955-61. PubMed ID: 9157991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of protein A and its fragment B on the catabolic and Fc receptor sites of IgG.
    Dima S; Medeşan C; Moţa G; Moraru I; Sjöquist J; Gheţie V
    Eur J Immunol; 1983 Aug; 13(8):605-14. PubMed ID: 6884420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of human C3a, C4a, and C5a anaphylatoxins by protein A of Staphylococcus aureus and immobilized protein A reagents used in serotherapy of cancer.
    Langone JJ; Das C; Bennett D; Terman DS
    J Immunol; 1984 Aug; 133(2):1057-63. PubMed ID: 6610702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
    Bradley MO; Webb NL; Anthony FH; Devanesan P; Witman PA; Hemamalini S; Chander MC; Baker SD; He L; Horwitz SB; Swindell CS
    Clin Cancer Res; 2001 Oct; 7(10):3229-38. PubMed ID: 11595719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of tumor-reactive immunotoxins in tumor-bearing mice: effect of antibody valency and deglycosylation of the ricin A chain on clearance and tumor localization.
    Fulton RJ; Tucker TF; Vitetta ES; Uhr JW
    Cancer Res; 1988 May; 48(9):2618-25. PubMed ID: 3258546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunization with targeted fusion anticaries DNA vaccine via intramuscular route:experiment with murine].
    Yu F; Fan MW; Xu QA; Jia R; Guo JH; Bian Z; Chen Z; Peng B; Fan B
    Zhonghua Yi Xue Za Zhi; 2004 May; 84(9):754-9. PubMed ID: 15200917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
    Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
    J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model.
    Weil-Hillman G; Runge W; Jansen FK; Vallera DA
    Cancer Res; 1985 Mar; 45(3):1328-36. PubMed ID: 3971376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A model for the formation and interconversion of protein A-immunoglobulin G soluble complexes.
    Hanson DC; Schumaker VN
    J Immunol; 1984 Mar; 132(3):1397-409. PubMed ID: 6693770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice.
    Ran S; He J; Huang X; Soares M; Scothorn D; Thorpe PE
    Clin Cancer Res; 2005 Feb; 11(4):1551-62. PubMed ID: 15746060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.
    Veronese FM; Schiavon O; Pasut G; Mendichi R; Andersson L; Tsirk A; Ford J; Wu G; Kneller S; Davies J; Duncan R
    Bioconjug Chem; 2005; 16(4):775-84. PubMed ID: 16029018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgG-protein A complexes modulate thymidine incorporation into DNA of antibody and complement-stimulated cells.
    Shearer WT; Green CG; Patel P; Langone JJ
    J Immunol; 1984 May; 132(5):2279-84. PubMed ID: 6715880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumoricidal response following perfusion over immobilized protein A: identification of immunoglobulin oligomers in serum after perfusion and their partial characterization.
    Balint J; Ikeda Y; Langone JJ; Shearer WT; Daskal I; Meek K; Cook G; Henry J; Terman DS
    Cancer Res; 1984 Feb; 44(2):734-43. PubMed ID: 6607106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
    Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
    Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
    Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.